The interleukin 1 inhibitor canakinumab in the treatment of cryopyrin-associated periodic syndromes (CAPS): clinical experience

Interleukin (IL) 1βis a major mediator of cryopyrin-associated periodic syndrome (CAPS). In this connection, the experience with IL-1 inhibitors used in patents with CAPS is being accumulated worldwide. Canakinumab was approved by FDA and EMEA in 2009 to treat CAPS and registered in the Russian Fede...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Svetlana Olegovna Salugina, E. S. Fedorov, N. N. Kuzmina, E. Yu. Zakharova
Médium: Artigo
Jazyk:Russo
Vydáno: IMA-PRESS LLC 2014-12-01
Edice:Современная ревматология
Témata:
cryopyrin-associated periodic syndrome
treatment
canakinumab
interleukin-1 inhibitors
On-line přístup:https://mrj.ima-press.net/mrj/article/view/570
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky